Leerink Partners Maintains Outperform on Jazz Pharmaceuticals, Raises Price Target to $225

Benzinga Newsdesk www.benzinga.com Positive 89.9%

Neg 0% Neu 0% Pos 89.9%

Leerink Partners analyst Marc Goodman maintains Jazz Pharmaceuticals (NASDAQ:JAZZ) with a Outperform and raises the price target from $215 to $225.